Hutchmed, Іnnovent Biologics Combination Injection Receives Conditional Approval in China

MT Newswires Live12-03

Hutchmed (China) (HKG:0013) and Іnnovent Biologics (HKG:1801) said the new drug application for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab injection) was granted conditional approval in China for the treatment of endometrial cancer with mismatch repair proficient tumors.

The combination had previously been awarded priority review status and breakthrough therapy designation by the National Medical Products Administration of China, a Tuesday Hong Kong bourse filing said.

The approval followed the results of a phase 2 clinical study of the combination which showed objective response rate and disease control rate of 35.6% and 88.5% respectively while the adverse events are similar to that of alike immunotherapy and antiangiogenic agents combination treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488913794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488913794","market":"us","top_or_hot":-1,"title":"Hutchmed, Іnnovent Biologics Combination Injection Receives Conditional Approval in China","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (China) (HKG:0013) and Іnnovent Biologics (HKG:1801) said the new drug application for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab injection) was granted conditional approval in China for the treatment of endometrial cancer with mismatch repair proficient tumors.</p><p>The combination had previously been awarded priority review status and breakthrough therapy designation by the National Medical Products Administration of China, a Tuesday Hong Kong bourse filing said.</p><p>The approval followed the results of a phase 2 clinical study of the combination which showed objective response rate and disease control rate of 35.6% and 88.5% respectively while the adverse events are similar to that of alike immunotherapy and antiangiogenic agents combination treatments.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed, Іnnovent Biologics Combination Injection Receives Conditional Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed, Іnnovent Biologics Combination Injection Receives Conditional Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 19:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hutchmed (China) (HKG:0013) and Іnnovent Biologics (HKG:1801) said the new drug application for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab injection) was granted conditional approval...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488913794","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488913794","pubTimestamp":1733226213,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed   and nnovent Biologics  said the new drug application for ELUNATE  in combination with TYVYT  was granted conditional approval in China for the treatment of endometrial cancer with mismatch repair proficient tumors.The combination had previously been awarded priority review status and breakthrough therapy designation by the National Medical Products Administration of China, a Tuesday Hong Kong bourse filing said.The approval followed the results of a phase 2 clinical study of the combination which showed objective response rate and disease control rate of 35.6% and 88.5% respectively while the adverse events are similar to that of alike immunotherapy and antiangiogenic agents combination treatments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1587":"次新股","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1588":"回港中概股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1589":"北水核心资产","00013":"和黄医药","BK1191":"制药","BK1161":"生物科技","01801":"信达生物"},"translate_title":"和黄医药，І nnovent生物制剂组合注射液在中国获得有条件批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"01801":0.9},"content_text":"Hutchmed (China) (HKG:0013) and Іnnovent Biologics (HKG:1801) said the new drug application for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab injection) was granted conditional approval in China for the treatment of endometrial cancer with mismatch repair proficient tumors.The combination had previously been awarded priority review status and breakthrough therapy designation by the National Medical Products Administration of China, a Tuesday Hong Kong bourse filing said.The approval followed the results of a phase 2 clinical study of the combination which showed objective response rate and disease control rate of 35.6% and 88.5% respectively while the adverse events are similar to that of alike immunotherapy and antiangiogenic agents combination treatments.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488913794"}